CD133+ subpopulation of the HT1080 human fibrosarcoma cell line exhibits cancer stem-like characteristics

Feng,Bao‑Hua; Liu,Ai‑Guo; Gu,Wen‑Guang; Deng,Liang; Cheng,Xian‑Gyang; Tong,Tie‑Jun; Zhang,Hong‑Zhi

doi:10.3892/or.2013.2486

CD133+ subpopulation of the HT1080 human fibrosarcoma cell line exhibits cancer stem-like characteristics

Authors:
- Bao‑Hua Feng
- Ai‑Guo Liu
- Wen‑Guang Gu
- Liang Deng
- Xian‑Gyang Cheng
- Tie‑Jun Tong
- Hong‑Zhi Zhang
View Affiliations

Affiliations: Department of Orthopedic Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: May 23, 2013 https://doi.org/10.3892/or.2013.2486
Pages: 815-823

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The cancer stem cell (CSC) theory holds that a minority population within tumors possesses stem cell properties of self-renewal and multilineage differentiation capacity and provides the initiating cells from which tumors are derived and sustained. However, verifying the existence of these CSCs has been a significant challenge. The CD133 antigen is a pentaspan membrane glycoprotein proposed to be a CSC marker for cancer-initiating subpopulations in the brain, colon and various other tissues. Here, CD133+ cells were obtained and characterized from the HT1080 cell line to determine the utility of this marker for isolating CSCs from human fibrosarcoma cells. In this study, CD133+ cells were separated from HT1080 cells using magnetic beads and characterized for their proliferation rate and resistance to chemotherapeutic drugs, cisplatin and doxorubicin, by MTS assay. Relative expression of tumor-associated genes Sox2, Oct3/4, Nanog, c-Myc, Bmi-1 and ABCG2 was measured by real-time polymerase chain reaction (PCR). Clonal sphere formation and the ability of CD133+ cells to initiate tumors in BALB/c nude mice was also evaluated. We found that CD133+ cells showed a high proliferation rate, increased resistance to chemotherapy drugs and overexpression of tumor-associated genes compared with these features in CD133- cells. Additionally, CD133+ cells were able to form spherical clusters in serum-free medium with high clonogenic efficiency, indicating a significantly greater tumor-initiating potential when compared with CD133- cells. These findings indicate that CD133+ cells identified within the HT1080 human fibrosarcoma cell line possess many CSC properties and may facilitate the development of improved therapies for fibrosarcoma.

View Figures

View References

1	Bahrami A and Folpe AL: Adult-type fibrosarcoma: a reevaluation of 163 putative cases diagnosed at a single institution over a 48-year period. Am J Surg Pathol. 34:1504–1513. 2010.PubMed/NCBI
2	Fisher C: The value of electron microscopy and immunohistochemistry in the diagnosis of soft tissue sarcomas: a study of 200 cases. Histopathology. 16:441–454. 1990. View Article : Google Scholar : PubMed/NCBI
3	Pritchard DJ, Soule EH, Taylor WF and Ivins JC: Fibrosarcoma - a clinicopathologic and statistical study of 199 tumors of the soft tissues of the extremities and trunk. Cancer. 33:888–897. 1974. View Article : Google Scholar : PubMed/NCBI
4	Pritchard DJ, Sim FH, Ivins JC, et al: Fibrosarcoma of bone and soft tissues of the trunk and extremities. Orthop Clin North Am. 8:869–881. 1977.PubMed/NCBI
5	Scott SM, Reiman HM, Pritchard DJ and Ilstrup DM: Soft tissue fibrosarcoma. A clinicopathologic study of 132 cases. Cancer. 64:925–931. 1989. View Article : Google Scholar : PubMed/NCBI
6	Wibmer C, Leithner A, Zielonke N, et al: Increasing incidence rates of soft issue sarcomas? A population-based epidemiologic study and literature review. Ann Oncol. 21:1106–1111. 2010. View Article : Google Scholar : PubMed/NCBI
7	Al-Hajj M and Clarke MF: Self-renewal and solid tumor stem cells. Oncogene. 23:7274–7282. 2004. View Article : Google Scholar : PubMed/NCBI
8	Hermann PC, Bhaskar S, Cioffi M and Heeschen C: Cancer stem cells in solid tumors. Semin Cancer Biol. 20:77–84. 2010. View Article : Google Scholar : PubMed/NCBI
9	Bansal N and Banerjee D: Tumor initiating cells. Curr Pharm Biotechnol. 10:192–196. 2009. View Article : Google Scholar
10	O’Brien CA, Kreso A and Dick JE: Cancer stem cells in solid tumors: an overview. Semin Radiat Oncol. 19:71–77. 2009.
11	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
12	Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
13	Al-Hajj M, Wicha MS, Benito-Hernandez A, et al: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
14	Singh SK, Clarke ID, Terasaki M, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821–5828. 2003.PubMed/NCBI
15	Collins AT, Berry PA, Hyde C, et al: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI
16	Chen SY, Huang YC, Liu SP, et al: An overview of concepts for cancer stem cells. Cell Transplant. 20:113–120. 2011. View Article : Google Scholar : PubMed/NCBI
17	Gibbs CP, Kukekov VG, Reith JD, et al: Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia. 7:967–976. 2005. View Article : Google Scholar : PubMed/NCBI
18	Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007. View Article : Google Scholar : PubMed/NCBI
19	Ciavarella S, Milano A, Dammacco F and Silvestris F: Targeted therapies in cancer. BioDrugs. 24:77–88. 2010. View Article : Google Scholar
20	Mizrak D, Brittan M and Alison M: CD133: molecule of the moment. J Pathol. 214:3–9. 2008. View Article : Google Scholar : PubMed/NCBI
21	Ceder JA, Jansson L, Ehrnström RA, et al: The characterization of epithelial and stromal subsets of candidate stem/progenitor cells in the human adult prostate. Eur Urol. 53:524–531. 2008. View Article : Google Scholar
22	Curley MD, Therrien VA, Cummings CL, et al: CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 27:2875–2883. 2009.PubMed/NCBI
23	Rutella S, Bonanno G, Procoli A, et al: Cells with characteristics of cancer stem/progenitor cells expresses the CD133 antigen in human endometrial tumors. Clin Cancer Res. 15:4299–4311. 2009. View Article : Google Scholar : PubMed/NCBI
24	Suvà ML, Riggi N, Stehle JC, et al: Identification of cancer stem cells in Ewing’s sarcoma. Cancer Res. 69:1776–1781. 2009.
25	Tirino V, Desiderio V, d’Aquino R, et al: Detection and characterization of CD133⁺ cancer stem cells in human solid tumors. PLoS One. 3:e34692008. View Article : Google Scholar : PubMed/NCBI
26	Wang J, Wang H, Li Z, et al: c-Myc is required for maintenance of glioma cancer stem cells. PLoS One. 3:e37692008. View Article : Google Scholar : PubMed/NCBI
27	Hadnagy A, Gaboury L, Beaulieu R and Balicki D: SP analysis may be used to identify cancer stem cell populations. Exp Cell Res. 312:3701–3710. 2006. View Article : Google Scholar : PubMed/NCBI
28	Moserle L, Ghisi M, Amadori A and Indraccolo S: Side population and cancer stem cells: therapeutic implications. Cancer Lett. 288:1–9. 2010. View Article : Google Scholar : PubMed/NCBI
29	Wu C and Alman BA: Side population cells in human cancers. Cancer Lett. 268:1–9. 2008. View Article : Google Scholar
30	Kelberman D, de Castro SC, Huang S, et al: SOX2 plays a critical role in the pituitary, forebrain, and eye during human embryonic development. J Clin Endocrinol Metab. 93:1865–1873. 2008. View Article : Google Scholar
31	Maruyama M, Ichisaka T, Nakagawa M and Yamanaka S: Differential roles for Sox15 and Sox2 in transcriptional control in mouse embryonic stem cells. J Biol Chem. 280:24371–24379. 2005. View Article : Google Scholar : PubMed/NCBI
32	Medvedev SP, Shevchenko AI, Mazurok NA and Zakiian SM: OCT4 and NANOG are the key genes in the system of pluripotency maintenance in mammalian cells. Genetika. 44:1589–1608. 2008.(In Russian).
33	Tokuzawa Y, Kaiho E, Maruyama M, et al: Fbx15 is a novel target of Oct3/4 but is dispensable for embryonic stem cell self-renewal and mouse development. Mol Cell Biol. 23:2699–2708. 2003. View Article : Google Scholar : PubMed/NCBI
34	Brunk BP, Martin EC and Adler PN: Drosophila genes posterior sex combs and suppressor two of zeste encodes proteins with homology to the murine bmi-1 oncogene. Nature. 353:351–353. 1991. View Article : Google Scholar : PubMed/NCBI
35	Iwama A, Oguro H, Negishi M, et al: Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity. 21:843–851. 2004. View Article : Google Scholar : PubMed/NCBI
36	Lessard J and Sauvageau G: Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 423:255–260. 2003. View Article : Google Scholar : PubMed/NCBI
37	Choi CH: ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 5:302005. View Article : Google Scholar : PubMed/NCBI
38	Vasiliou V, Vasiliou K and Nebert DW: Human ATP-binding cassette (ABC) transporter family. Hum Genomics. 3:281–290. 2009. View Article : Google Scholar : PubMed/NCBI
39	Jin Y, Bin ZQ, Qiang H, et al: ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J Cancer Res Clin Oncol. 135:1369–1376. 2009. View Article : Google Scholar : PubMed/NCBI
40	Liang Y, Russell I, Walworth C and Chen C: Gene expression in stem cells. Crit Rev Eukaryot Gene Expr. 19:289–300. 2009. View Article : Google Scholar : PubMed/NCBI
41	Pascal LE, Oudes AJ, Petersen TW, et al: Molecular and cellular characterization of ABCG2 in the prostate. BMC Urol. 7:62007. View Article : Google Scholar
42	Takara K, Sakaeda T and Okumura K: An update on overcoming MDR1 mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des. 12:273–286. 2006. View Article : Google Scholar : PubMed/NCBI
43	Sharom FJ: ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 9:105–127. 2008. View Article : Google Scholar : PubMed/NCBI